A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 707-713

  Zhang, Weijun ^a   Zhang, Tong ^a   Turk, Mary Jo ^a   Usherwood, Edward J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Herpesvirus vaccine; Immune surveillance; Persistent virus melanoma tumor immunotherapy; Tumor vaccine

Indexed keywords

VIRUS VACCINE; CANCER VACCINE; EPITOPE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; GAMMAHERPESVIRINAE; IMMUNIZATION; MELANOMA B16; MOUSE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVERTANT; TUMOR IMMUNITY; VACCINATION; VACCINIA VIRUS; VIRUS MUTANT; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SEPARATION; CHRONIC DISEASE; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HERPES VIRUS INFECTION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CHRONIC DISEASE; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; TRANSFECTION; VIRAL PROTEINS;

EID: 77950496865     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0790-8     Document Type: Article

References (17)

1. Arien PM, Gulley JL, Madan RA, Hodge JW, Schlom J (2007) Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 27:451-462
2. Wherry EJ, Ahmed R (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78:5535-5545 (Pubitemid 38661640)
3. Fuse S, Molloy MJ, Usherwood EJ (2008) Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions. Crit Rev Immunol 28:159-183 (Pubitemid 351507427)
4. Obar JJ, Fuse S, Leung EK, Bellfy SC, Usherwood EJ (2006) Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol 80:8303-8315 (Pubitemid 44384844)
5. Fowler P, Efstathiou S (2004) Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73. J Gen Virol 85:609-613 (Pubitemid 38379862)
6. Moorman NJ, Wilier DO, Speck SH (2003) The gammaherpesvirus 68 latency-associated nuclear antigen, homolog is critical for the establishment of splenic latency. J Virol 77:10295-10303
7. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA (1992) Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J Gen Virol 73:2347-2356
8. Fowler P, Marques S, Simas JP, Efstathiou S (2003) ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J Gen Virol 84:3405-3416 (Pubitemid 37540768)
9. Stevenson PG, Belz GT, Castrucci MR, Altman JD, Doherty PC (1999) A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. Proc Natl Acad Sci USA 96:9281-9286
10. Fuse S, Obar JJ, Bellfy S, Leung EK, Zhang W, Usherwood EJ (2006) CD80 and CD86 control antiviral CD8 + T-cell function, and immune surveillance of murine gammaherpesvirus 68. J Virol 80:9159-9170 (Pubitemid 44359988)
11. Obar JJ, Crist SG, Gondek DC, Usherwood EJ (2004) Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J Immunol 172:1213-1219
12. Zhang T, Lemoi BA, Sentirian CL (2005) Chimeric NK-receptorbearing T cells mediate antitumor immunotherapy. Blood 106:1544-1551 (Pubitemid 41208564)
13. Liu L, Flano E, Usherwood EJ, Surman S, Blackman MA, Woodland DL (1999) Lytic cycle T cell epitopes are expressed in two distinct phases during MHV-68 infection. J Immunol 163:868-874 (Pubitemid 29328096)
14. Harrington LE, Most Rv R, Whitton JL, Ahmed R (2002) Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76:3329-3337
15. Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, Dunbar PR, Sette A, Harris AL, Cerundolo V (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia. Ankara J Immunol 175:8431-8437
16. Usherwood EJ, Ross AJ, Allen DJ, Nash AA (1996) Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J Gen. Virol 77:627-630
17. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270